End stage liver disease and liver cancer are major health concerns for individuals with hepatitis C virus (HCV) infection. Current therapies for HCV aim to halt and reverse the progression of liver injury. These therapies are based on interferon (IFN) and are expected to continue to be based on IFN for the foreseeable future. Both host and viral factors influence treatment outcome. Published data show that viral point mutations in the core gene are associated with treatment failure and insulin resistance. Of great interest, these same mutations (in codons 70 and 91) are associated with the development of liver cancer. These highly specific viral point mutations provide a unique opportunity to investigate HCV-related liver damage and treatment failure at the molecular level. We recently discovered that the disease-associated mutations in codons 70 and 91 have a profound effect on HCV gene expression: They alter the level of two newly identified viral proteins, 70 minicore protein and 91 minicore protein. In a major finding, we discovered that the disease-associated mutation in codon 91 enhances the internal initiation of protein synthesis at codon 91. Our data add to earlier evidence that HCV uses "divergent" modes of translation initiation to evade cellular antiviral defenses and to increase viral fitness. To account for minicore production, we propose that the core gene contains an extensive and highly conserved translational machine that promotes the internal initiation of protein synthesis at specific sites, driving minicore synthesis and enhancing IFN resistance and viral persistence. The impact of mutations in codons 70 and 91 on the IFN sensitivity of viruses and on the structure and function of minicore proteins will be investigated in Aim I. The properties of the translational machine and the effect of the disease-associated mutations on its activity will be determined in Aim II. Accomplishment of our Aims will fill fundamental gaps in the understanding of the HCV life cycle and provide basic information needed to design interventions to block the action of the translational machine and to inhibit the effects of the minicore proteins in patients.
Clinical studies of liver disease patients with chronic hepatitis C virus (HCV) infection provide vital information about viral and host determinants of treatment outcome and disease progression. It is thus highly significant that clinical studies have identified two mutations in HCV that are strongly associated with treatment failure and the development of liver cancer. This project investigates the action of these mutations at the molecular level, with the ultimate goal of developing interventions to block the effects of the viral genes influenced by the disease- associated mutations. Clinical studies of liver disease patients with chronic hepatitis C virus (HCV) infection provide vital information about viral and host determinants of treatment outcome and disease progression. It is thus highly significant that clinical studies have identified two mutations in HCV that are strongly associated with treatment failure and the development of liver cancer. This project investigates the action of these mutations at the molecular level, with the ultimate goal of developing interventions to block the effects of the viral genes influenced by the disease- associated mutations.
|Sefcik, Roberta K; Bichoupan, Kian; Martel-Laferrière, Valérie et al. (2014) Telaprevir activity in treatment-naive patients infected with hepatitis C virus genotype 4. J Infect Dis 210:1855-6|
|Ge, Xiaodong; Antoine, Daniel J; Lu, Yongke et al. (2014) High mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver disease (ALD). J Biol Chem 289:22672-91|
|Branch, Andrea D; Barin, Burc; Rahman, Adeeb et al. (2014) Vitamin D status of human immunodeficiency virus-positive patients with advanced liver disease enrolled in the solid organ transplantation in HIV: multi-site study. Liver Transpl 20:156-64|
|Bichoupan, Kian; Martel-Laferriere, Valerie; Sachs, David et al. (2014) Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology 60:1187-95|
|Fierer, Daniel S; Dieterich, Douglas T; Mullen, Michael P et al. (2014) Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis 58:873-9|
|Li, Lily; Lin, Marvin; Krassilnikova, Maria et al. (2014) Effect of cholecalciferol supplementation on inflammation and cellular alloimmunity in hemodialysis patients: data from a randomized controlled pilot trial. PLoS One 9:e109998|
|Martel-Laferriere, V; Brinkley, S; Bichoupan, K et al. (2014) Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med 15:108-15|
|Bichoupan, K; Schwartz, J M; Martel-Laferriere, V et al. (2014) Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther 39:209-16|
|Crismale, James F; Martel-Laferrière, Valérie; Bichoupan, Kian et al. (2014) Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int 34:1018-24|
|Branch, Andrea D; Drye, Lea T; Van Natta, Mark L et al. (2013) Evaluation of hepatitis C virus as a risk factor for HIV-associated neuroretinal disorder. Clin Infect Dis 57:1618-25|
Showing the most recent 10 out of 14 publications